Clinical Trials Browser

copper dotatate CU-64 × Clear all

NCT06379217 2026-05-11

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Phase 1 Active not recruiting

EndocrineGenitourinary

Metastatic Neuroendocrine Prostate Cancer

NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Phase 1 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04711135 2026-02-12

NETTER-P

Phase 2 Active not recruiting

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Phase 2 Unknown

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04949282 2022-12-23

SEPTRALU

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Phase NA Completed

Neuroendocrine Tumors